An epitope focused nanoparticle vaccine for MRSA and biodefense

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41AI122594-01
Agency Tracking Number: R41AI122594
Amount: $546,129.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NIAID
Solicitation Number: PA14-072
Timeline
Solicitation Year: 2014
Award Year: 2016
Award Start Date (Proposal Award Date): 2016-01-15
Award End Date (Contract End Date): 2018-12-31
Small Business Information
3030 BUNKER HILL ST STE 350, San Diego, CA, 92109-5757
DUNS: 160242579
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 JON OSCHERWITZ
 (734) 769-7100
 joscher@umich.edu
Business Contact
 JOYCE JONES
Phone: (858) 242-1524
Email: jjones@vlp-biotech.com
Research Institution
 UNIVERSITY OF MICHIGAN
 1600 Huron Parkway
2nd Floor
Ann Arbor, MI, 48109-5001
 Nonprofit college or university
Abstract
DESCRIPTION provided by applicant Overall Staphylococcus aureus is a gram positive bacteria which possesses a multitude of virulence factors It is a frequent and severe pathogen in hospitals and of increasing concern in the community where it results in severe skin infections pneumonia bacterial endocarditis and sepsis A significant proportion of these infections are the result of methicillin resistant S aureus MRSA We have developed a highly immunogenic nanoparticle vaccine capable of rapidly eliciting antibody against the pore neutralizing determinant PND within alpha toxin AT a ubiquitous and critical virulence factor of MRSA Previous work has demonstrated that Ab against the PND is highly efficacious in preventing tissue injury and bacterial growth in a rigorous mouse dermonecrosis model and in protecting mice in a lethal model of S aureus pneumonia In this project we will develop a bivalent vaccine which targets both the PND as well as critical epitopes within both Staphylococcal enterotoxin B and C which have been shown to be particularly important virulence factors in MRSA infections but also have the potential to be formulated as bioweapons The vaccine emerging from these studies will be uniquely efficacious against MRSA infections and for protection against the potential for SEB and SEC intoxication PUBLIC HEALTH RELEVANCE Infections with methicillin resistant S aureus or MRSA constitute a public health imperative Emerging from these studies will be a uniquely efficacious nanoparticle vaccine against critical virulence factors which will be efficacious in preventing MRSA

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government